Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer
Authors:
- 27 July 2021
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (11) , 1299-1313
Abstract
Purpose Screening for prostate cancer may have limited impact on decreasing prostate cancer-related mortality. A major disadvantage is overdiagnosis, whereby lesions are identified that would not have become evident during the man’s lifetime if screening had not taken place. The present study aims to estimate the rate of overdiagnosis using Finnish data from the European randomized trial of prostate cancer screening. Methods We used data from 80,149 men randomized to a screening or a control group, distinguishing four birth cohorts. We used the “catch-up method” to identify when the difference in the cumulative incidence of prostate cancer between the screening and control groups had stabilized, implying that the screening has no further effect. We define the overdiagnosis rate to be the relative excess cumulative incidence in the screened group at that point. As an independent method, we also examined the diagnosis rates of T1c tumors as an indicator of early tumors detected by PSA. Results The estimates of overdiagnosis rates from the catch-up method using the full period of available follow-up ranged between cohorts from 2.3% to 15.4%, and the T1c analysis gave very similar results. Conclusion Some overdiagnosis has occurred, but there is uncertainty about its extent. A long follow-up is required to demonstrate the full impact of screening. We evaluated the overdiagnosis rates at a population level, associated with being offered screening, taking account of contamination (screening among the controls). The overall evaluation of screening should incorporate mortality benefit, cost-effectiveness, and quality of life.Keywords
All Related Versions
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- the academy of finland (Grant No 260931)
- The Cancer Society of Finland
- Competitive State Research Funding administered by Pirkanmaa University Hospital special responsibility area.
This publication has 33 references indexed in Scilit:
- Lead-time in the European Randomised Study of Screening for Prostate CancerEuropean Journal of Cancer, 2010
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screeningBritish Journal of Cancer, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI: Journal of the National Cancer Institute, 2009
- Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence TrendsBiometrics, 2008
- Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic reviewThe Lancet Oncology, 2007
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007
- A population model of prostate cancer incidenceStatistics in Medicine, 2006
- Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994)European Journal of Cancer, 2005